26th May 2023
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
23rd May 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd May 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th March 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd March 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st December 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th November 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd November 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th November 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th August 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th June 2022
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
12th May 2022
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
3rd May 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
19th April 2022
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity
5th April 2022
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
25th January 2022
Curium to become major player in the supply on non carrier added Lu-177
15th December 2021
Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer
27th October 2021
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
24th August 2021
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
1st June 2021